Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ ...
By Sneha S K and Kunal Das March 25 (Reuters) - The U.S. Food and Drug Administration has approved Denali Therapeutics' ...
Investor's Business Daily on MSN
Denali solved a major challenge in treating a rare genetic disease. Now, shares are flying.
Denali Therapeutics solved a major challenge in Hunter syndrome treatment. Now it's ready to take its technology further.
The FDA has approved Denali Therapeutics’ enzyme replacement therapy for a genetic lysosomal storage disease after a string ...
View Denali Therapeutics Inc. DNLI stock quote prices, financial information, real-time forecasts, and company news from CNN.
Denali Therapeutics said Takeda Pharmaceuticals terminated the companies' agreement to co-develop and commercialize a dementia drug. Denali would regain full ownership of DNL593, an investigational ...
Avlayah is the first Hunter syndrome therapy approved to address the condition’s neurologic complications, according to Tracy ...
Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technologyResults from ongoing Phase 1/2 study in patients with F ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results